Abstract 30P
Background
Metastatic breast cancer (mBC) remains a leading cause of cancer-related deaths among women globally. Despite advances, many treatments fail to improve patient outcomes, emphasizing the need for innovative approaches and reliable biomarkers to better predict treatment response. Recent studies show that neutrophils play a critical role in cancer, with low density neutrophils (LDN) acting as key modulators in the tumor microenvironment. LDN are linked to tumor growth and metastasis, contributing to an immunosuppressive environment that supports cancer progression. Here, we investigated the clinical significance of LDN in breast cancer (BC) by assessing their association with disease progression and patient outcomes.
Methods
We analysed blood samples from 146 BC patients (78 non-metastatic, 68 metastatic), isolating both LDN and high-density neutrophils (HDN, conventional neutrophils) by density gradient centrifugation. Flow cytometry was used to quantify and characterize the populations.
Results
Our results show significant LDN accumulation in BC patients’ blood, particularly those with metastatic disease. Importantly, elevated LDN levels were linked to reduced life expectancy in these patients, regardless of metastatic site (bone, lung or brain). Moreover, the increase in LDN levels was often accompanied by a decrease in HDN, leading to an imbalance favoring protumor neutrophils. Additionally, preliminary data from a small cohort of triple-negative BC patients (n=7, ongoing recruitment) undergoing immunotherapy suggest that higher pre-treatment LDN levels may predict poorer treatment response. This early finding points to LDN’ potential as predictive biomarkers for immunotherapy efficacy in BC.
Conclusions
Our study highlights the prognostic value of LDN in BC, with elevated levels linked to advanced disease and worse clinical outcomes. These findings suggest that LDN could serve as valuable biomarkers for monitoring disease progression and predict treatment response, identifying patients at greater risk. Ultimately, incorporating LDN assessment into clinical practice may guide treatment strategies, offering a more personalized approach to BC management and potentially improving therapeutic outcomes.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
95P - Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study
Presenter: Nicolas Girard
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract